Jubilant Pharmova’s contract manufacturing arm, Jubilant HollisterStier (JHS), has launched its third Sterile Fill & Finish line at the Spokane Manufacturing Facility in Washington, U.S.—a major leap in its North American expansion strategy.
A Milestone in Expansion
The new line has already produced its first commercial batch, marking the start of revenue generation. This addition boosts capacity by 50%, moving JHS closer to doubling its total sterile injectable output once the fourth line goes live.
Advanced Tech and Regulatory Strength
- Equipped with next-gen isolator technology for superior sterility, precision, and efficiency.
- Designed to meet stringent global regulatory standards (U.S. FDA, EMA, PMDA Japan, Health Canada, ANVISA, etc.).
- Backed by a US$132 million investment, reflecting JHS’s commitment to innovation, quality, and supply chain resilience.
Strengthening U.S. Supply Chain
The expansion comes as global pharma companies seek reliable U.S.-based manufacturing partners, especially amid new tariff policies. By enhancing domestic capacity, JHS is helping reduce offshore dependency and strengthen U.S. health security.
“With the third line operational and the fourth on the way, we’re not just doubling capacity — we’re building a future of resilient, high-quality U.S. manufacturing,”
- Chris Preti, CEO – CDMO Sterile Injectables, Jubilant HollisterStier.
Market Traction and Trust
- Growing RFP demand from large innovator pharma companies.
- Expected full utilization in three years.
- 92% customer retention rate and partnerships with 5 of the top 20 global pharma players.
